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ABSTRACT
Objectives: We examined the association of
plasminogen activator inhibitor-1 (PAI-1) levels with
colorectal cancer, breast cancer, acute coronary
syndrome (ACS) and ischaemic stroke.
Design: Nested case-cohort study.
Setting: The European Prospective Investigation into
Cancer and Nutrition-Italy cohort.
Participants: A centre-stratified random sample of 850
participants (286 men, 564 women) was selected as
subcohort and compared with 303 colorectal cancers,
617 breast cancers, 688 ACS and 158 ischaemic
strokes, in a mean follow-up of 9.11 years.
Main outcomes and measures: Primary incident
cases of colon cancer, breast cancer, ACS and
ischaemic stroke. PAI-1 levels were measured in citrated
plasma by ELISA. HR and 95% CI, adjusted by relevant
confounders and stratified by centre, were estimated by
a Cox regression model using Prentice method.
Results: Individuals in the highest compared with the
lowest quartile of PAI-1 had significantly increased risk
of colorectal cancer (RR=2.28; 95% CI 1.46 to 3.55; P
for trend<0.0012), breast cancer (HR=1.70; 95% CI
1.21 to 2.39; p<0.0055), ACS (HR=2.57; 95% CI 1.75 to
3.77; p<0.001) and ischaemic stroke (HR=2.27; 95% CI
1.28 to 4.03; p<0.0017), after adjustment for sex and
age. Additional adjustment for disease-specific
confounders, insulin or other metabolic variables did
not modify the associations. Risk of colon cancer was
stronger for men and for whole and distal colon
localisation. Risk for breast cancer was stronger in
postmenopausal women.
Conclusions: Our data provide the first evidence that
elevated levels of PAI-1 are potential risk factors for
colorectal and breast cancer and a common pathway for
cancer and cardiovascular disease.
INTRODUCTION
It has long been thought that there might be
a common ground, the so-called common
soil, in the pathogenesis of ischaemic cardio-
vascular disease and of certain types of
cancer, such as cancers of the gastrointestinal
tract and those whose growth is linked to
hormonal conditions (breast, uterus, ovary
and prostate cancer).1 2
Plasminogen activator inhibitor-1 (PAI-1) is
the main physiological inhibitor of tissue-type
(t-PA) and urokinase-type (u-PA) plasmino-
gen activator3 enzymes involved in blood
fibrinolysis as well as tissue remodelling. It is
produced by endothelial cells, liver cell,
smooth muscle cell, primary cultures of
human and murine adipocytes and stroma
cells.4
Strengths and limitations of this study
▪ Major strengths are the prospective design of the
study, the relative large sample size, the different
endpoints and the use of detailed information on
lifestyle, anthropometric and biological variables,
allowing to control for their possible confound-
ing effect.
▪ A limitation is that, as it occurs in the greatest
majority of large prospective cohort studies, for
each individual PAI-1 level could only be
assessed in a single plasma sample; thus, indi-
cations of long-term variation in these levels
since baseline are lacking.
▪ Another limitation is that samples were stored
after collection at −196°C, and assayed up to
17 years later, thus the possibility of a variable
PAI-1 concentration decay during long-term
storage cannot be excluded. However, recent
data indicate that long-term storage affects PAI-1
antigen levels to a negligible extent.
▪ It should be considered that association is not
necessarily equal to causation and PAI-1 could
be a by-product (or a marker) of an, as yet
undefined, ‘common soil’ mechanism.
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Impaired fibrinolytic activity secondary to elevated
plasma PAI-1 levels was associated with coronary heart
disease and stroke,5–7 although, not always was the asso-
ciation independent of other cardiovascular risk
factors.7–9 However, the 4G/5G polymorphism of PAI-1,
strongly associated with PAI-1 levels, may be a risk factor
for myocardial infarction in Caucasian and Asian
populations.10–12
A key role played by PAI-1 in tumour invasion and
angiogenesis has been recently demonstrated in
PAI-1-deficient mice, in which implanted malignant cells
were unable to induce vascularised tumours.13 Recent
work indicates that activation of the MET oncogene,
which drives invasion and metastasis in cancer, can
promote transcriptional upregulation of the PAI-1
gene.14 The PAI-1 expression, in turn, might prevent
excessive proteolysis and maintains extracellular matrix
integrity, which is necessary for capillary morphogenesis,
cell migration and invasion.15
Expression levels of PAI-1 are elevated in many cancers,
such as breast,16–18 ovarian19 and colorectal cancers.20
Furthermore, high levels of PAI-1 in the primary tumour
tissue of patients with various types of solid cancers cor-
relate with disease recurrence and reduced survival (for
review see Ref. 21). However, although there is some evi-
dence for the prognostic role of PAI-1 in cancer, no data
are apparently available on the predictive role of circulat-
ing PAI-1 levels on cancer risk in the population.
Case-cohort studies nested within longitudinal cohorts
can allow to investigate simultaneously risk factors for
different diseases and to test the hypothesis of PAI-1 as a
relevant mediator of the common soil between cancer
and coronary artery disease.
We conducted a case-cohort study nested in the
European Prospective Investigation into Cancer and
Nutrition (EPIC) Italy cohort22 23 to examine the pos-
sible relationships of plasma levels of PAI-1 with the risk
of colorectal cancers, breast cancer, acute coronary syn-
drome (ACS) and ischaemic stroke. Moreover, we exam-
ined whether risks associated to PAI-1 levels were
modified by anthropometric and metabolic factors, pre-
viously shown to be related to circulating PAI-1 levels.24
This study is the first to our knowledge which formally
evaluates the ‘common soil’ hypothesis and by far the
largest prospective study to date, investigating the asso-
ciations of PAI-1 with risk of diseases.
MATERIALS AND METHODS
Study population and data collection
The EPIC-Italy cohort analysed consists of 34 148 partici-
pants recruited prospectively in 1993–1998 by four of
five EPIC-Italy centres (Varese, Turin, Naples (women
only) and Ragusa).22 23 At baseline, all participants gave
written informed consent.
Detailed information was collected on lifestyle habits
by a standardised questionnaire and on usual diet in the
previous year by a food frequency questionnaire.25
Weight, height and blood pressure were measured using
standardised procedures.26 For each participant 0.5 mL
aliquots of 8 mL citrated plasma, 12 mL serum, 4 mL
packed red blood cell and 4 mL buffy coats were stored
in liquid nitrogen at −196°C.23
Study design
During a mean follow-up of 11.93 years, 303 cases (144
men and 159 women) of colorectal cancer, 617 cases (617
women) of breast cancer, 688 cases (471 men and 217
women) of ACS and 159 (men and women) cases of
ischaemic stroke were identified. Using a nested case-
cohort design,27 a centre-stratified sample of 850 non-cases
(286 men and 564 women) was randomly selected from
the parent cohort, forming a subcohort. Because of the
random selection from the parent cohort, this subcohort
also included two participants who had developed colorec-
tal cancer, 16 women with breast cancer, 14 participants
with ACS and 3 participants with ischaemic stroke.
Four different case-cohort settings were finally ana-
lysed: 303 cases and 850 non-cases for colorectal cancer
study, 617 cases and 564 non-cases for breast cancer
study, as only women were included, 688 cases and 840
non-cases for ACS study and 159 cases and 840 non-cases
for ischaemic stroke study.
In the ACS and ischaemic stroke studies, 10 partici-
pants were excluded from the non-cases subcohort since
they reported a history of ischaemic vascular disease at
baseline.
Case ascertainment
The end of follow-up was 31 December 2006 for Varese
and Naples; 31 December 2008 for Turin and Ragusa. In
total, 303 colorectal cancer cases and 616 cases of breast
cancer were identified.
In Varese, Turin and Ragusa, cancer incident cases were
identified by study cohort linkage to the databases of the
regional cancer registries, which are considered high
quality registries with nearly complete cancer recording.28
In Naples, incident cases were identified through linkage
to the regional archive of hospital discharges, and by
direct telephone contact where necessary.
Colon cancers were primary incident cases, identified
by the codes of the International Classification of
Diseases 10th Revision (ICD-10) as follows: proximal
(C18.0–18.5); distal (C18.6–C18.7) and overlapping or
unspecified sites (C18.8 and C18.9). Rectal cancers were
identified by the codes C19 (rectosygmoid junction) and
C20 (rectum). Anal cancers were excluded.
Breast cancers were primary incident cases, identified
by the codes of the ICD-10 as C50.
ACSs were primary incident cases of fatal and non-fatal
events of myocardial infarction, coronary revascularisa-
tion or both, and sudden death for an unspecified
cardiac event.
Suspected ACS deaths were identified when ICD-10
codes I20–I25, R96 and R99 were reported as the main
cause of death and also when codes E10–E14, I10–I13,
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I30, I31, I33–I38, I40, I42, I44–I51, I70–I74 and I77 were
reported together with I20–I25 as associated conditions.
After linkage with the hospital discharge files, all
records reporting ICD-9–clinical modification (CM)
410–414 codes and/or reperfusion procedure were con-
sidered. The disease was verified when acute myocardial
infarction, ACS or coronary revascularisation were noted
on the records, backed up by information on symptoms
at onset, concentrations of cardiac enzymes and tropo-
nins, and electrocardiogram data coded according to
the Minnesota Code.29
Suspected cerebrovascular disease deaths were identi-
fied when ICD-10 codes I60–I69 were reported as an
underlying cause of death or when codes E10–E14, I10–
I15, I46, I49 and I70 were reported as an underlying
cause in association with I60–I69. Fatal cerebrovascular
disease was assigned after verification against hospital
discharge and clinical records.
Participants with suspected cerebrovascular disease
were identified on hospital discharge forms by ICD-9–
CM codes 342, 433–434 or 436–438 or by procedure
codes for carotid revascularisation. Ischaemic throm-
botic stroke was diagnosed when brain infarction was
mentioned in the diagnosis and/or confirmed on the
basis of imaging examinations (CT or MRI).
Haemorrhagic stroke (n=68) were excluded.
Blood collection and laboratory procedures
PAI-1 levels were measured in citrated plasma collected
at recruitment by ELISA (Zymutest PAI-1, Hyphen
BioMed, Instrumentation Laboratory (IL) Milano, Italy).
The minimum detectable levels were 0.15 ng/mL.
Intra-assay variability was 3–8%. Interassay variabilities
were 8.2%, 9.8%, 9.9%, for high, low level standard and
pool, respectively. Insulin levels were measured by ELISA
(DRG Instruments GmbH, Germany). The range of the
assay was between 0 and 100 ng/mL. Intra-assay variation
was 1.8–2.6%. Interday coefficient of variation (CV) was
5.8%. High sensitivity C reactive protein (CRP) was mea-
sured in plasma, by a latex particle-enhanced immuno-
turbidimetric assay (IL Coagulation Systems on
ACL9000). Interday and intraday CV were 5.5% and
4.2%. Triglycerides and glucose were measured in
fasting plasma samples, with enzymatic colorimetric
method, using commercial kits (Instrumentation
Laboratory), with an automatic analyser (IL 350). CVs
for high and low level of external standard and for
in-house plasma pool were 5%, 7.9% and 3.5% for trigly-
cerides and 5%, 7.6% and 3.8% for glucose.
For all analyses, laboratory staff was blinded to the
case–control status of the samples.
Statistical analysis
Baseline characteristics of the subcohort members were
summarised using means with SDs for continuous vari-
ables and frequencies for categorical variables. PAI-1 levels
were classified into quartiles (based on the distributions in
the subcohort) with the lowest quartiles as reference. The
association between quartile of PAI-1 and environmental
or metabolic variables was assessed by the analysis of vari-
ance. To estimate the association between PAI-1 quartiles
and risk of colorectal or breast cancer or of ACS, Cox
proportional-hazard regression modified according to the
Prentice method was used, with age as the underlying time
scale.30 In the counting processes age was the underlying
time variable with ‘entry time’ defined as age at baseline
and ‘exit time’ as age at cancer, ACS or stroke event or cen-
soring. The significance of linear trends across quartiles
was tested by assigning each participant the median value
for the quartile and modelling this value as a value of a
continuous variable. HRs were also calculated analysing
PAI-1 levels as continuous variables with an increment of 1
SD. All models were stratified by centre. We fitted a minim-
ally adjusted model with age and sex as covariates (model
1); a multivariable model, with the additional covariates
body mass index (BMI, continuous), smoking status
(never, former, current), total physical activity31 (inactive,
moderately inactive, moderately active and active; entered
in the model as a continuous variable) and education (≤8,
>8 years); moreover menopausal status, parity and age at
menarche were used in breast cancer cases evaluation and
hypertension (yes, no), diabetes (yes, no) and hyperlipid-
aemia (yes, no) were used in ACS and stroke cases evalu-
ation (model 2). The models were further adjusted for
insulin levels (model 3) and finally further for glucose, tri-
glycerides and CRP (model 4). Multiplicative interaction
between PAI-1 levels (modelled as a continuous variable)
and sex (for evaluation of colon cancer and ACS cases) or
menopausal status (for evaluation of breast cancer cases)
in relation to cancer was tested with cross product terms.
We ran models for the whole cohort and the following
subcategories: men, women (the fully adjusted model
was further adjusted for menopausal status) and all
colon, proximal colon, distal colon and rectal cancer.
We also ran separate models for premenopausal and
postmenopausal women (48 women in perimenopausal
status were excluded).
The data analysis was generated using SAS/STAT soft-
ware, V.9.1.3 of the SAS System for Windows2009. SAS
Institute Inc and SAS are registered trademarks of SAS
Institute Inc, Cary, North Carolina, USA.
RESULTS
Table 1 shows the characteristics of the subcohort
according to quartiles of PAI-1 levels. PAI-1 levels were
positively associated with age, BMI, total cholesterol, tri-
glycerides and insulin. Moreover, participants in the
highest quartile of PAI-1 levels were more frequently
men, less active, less educated, postmenopausal if
women and more frequently smokers.
Colorectal cancer
Table 2 shows HR and 95% CIs for developing colorec-
tal cancer in relation to PAI-1 levels in the whole popula-
tion and by gender. After adjusting for age and sex and
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stratifying by centre a substantially higher risk for colon
cancer was seen for increasing levels of PAI-1
(HRVIvsI=2.28 (1.46 to 3.55). Additional adjustment for
BMI or waist circumference, smoking habits, total phys-
ical activity and education did not modify the results
(HRVIvsI=2.17 (1.34 to 3.50). Further adjustment for
insulin (ORVIvsI=0.20 (1.36 to 3.57) alone or with trigly-
cerides and CRP (HRVIvsI=1.84 (1.11 to 3.04), all meta-
bolic variables strongly associated with PAI-1 levels, did
not or only slightly reduced the association, which
remained statistically significant (figure 1). Following
exclusion of case participants who were diagnosed
within 1 year after blood collection (n=8) similar results
were obtained (HRIVvsI=1.70, 95% CI 1.02 to 2.84; P for
trend=0.048). The risk of colorectal cancer increased by
22% for each increase in 1 SD of PAI-1 levels.
After stratifying by gender, a stronger increase in risk
was seen in men, while in women the association was
never significant (P for interaction p=0.034 in model 3).
Further stratification of women for menopausal status
showed lack of significant association for premenopausal
as well as postmenopausal women (ORIVvs=2.27, 95% CI
0.78 to 6.62, P for trend=0.14 and 1.65, 95% CI 0.78 to
3.49, P for trend=0.27, respectively).
The analyses for each colorectal cancer subsite are
shown in online supplementary table I. For all colon and
Table 1 Baseline characteristics of subcohort members (n=850) according to quartiles of plasminogen activator inhibitor-1
(PAI-1)
Characteristic I (n=213) II (n=212) III (n=213) IV (n=212) P trend
PAI-1 No Quartiles of PAI-1
Median (ng/mL) 3.31 6.64 10.65 18.39
Range (ng/mL) 0.10–5.01 5.02–8.37 8.38–13.49 13.50–42.10
Mean±SD
Age (years) 48.9±8.7 49.7±7.8 50.5±7.6 51.1±7.5 0.0031
Body mass index (kg/m2) 24.2±3.2 25.3±3.6 26.5±3.7 28.6±4.3 <0.0001
Triglycerides (mg/dL) 102±56 115±59 138±83 179±101 <0.0001
Insulin (IU/mL) 8.0±5.0 8.9±6.8 10.1±7.3 11.2±8.0 <0.0001
Glucose (mg/dL) 90±14 93±14 97±22 105±29 <0.0001
C reactive protein (mg/L) 1.2±1.9 1.4±1.8 1.7±2.5 2.2±2.5 <0.0001
N (%)
Total physical activity 0.0078
Inactive 52 (24.4) 59 (27.8) 71 (33.3) 77 (36.3)
Moderately inactive 88 (41.3) 89 (42.0) 86 (40.4) 74 (34.9)
Moderately active 33 (15.5) 36 (17.0) 27 (12.7) 36 (17.0)
Active 40 (18.8) 28 (13.2) 29 (13.6) 25 (11.8)
Centre 0.16
Varese 89 (41.8) 67 (31.6) 71 (33.3) 79 (37.3)
Ragusa 38 (17.8) 30 (14.2) 46 (21.6) 37 (17.5)
Turin 59 (27.7) 90 (42.5) 64 (30.1) 50 (23.6)
Naples 27 (12.7) 25 (11.8) 32 (15.0) 46 (21.7)
Sex <0.0001
Men 43 (20.2) 74 (34.9) 77 (36.1) 92 (43.4)
Women 170 (79.8) 138 (65.1) 136 (63.9) 120 (56.6)
Education (years) 0.024
≤8 92 (43.2) 102 (48.1) 110 (51.6) 114 (53.8)
>8 121 (56.8) 110 (51.9) 103 (48.4) 98 (46.2)
Smoking status 0.013
Current smoker 42 (19.7) 69 (32.6) 54 (25.4) 61 (28.8)
Ex-smoker 53 (24.9) 50 (23.6) 52 (24.4) 69 (32.6)
Never smoker 118 (55.4) 93 (43.8) 107 (50.2) 82 (38.7)
Menopausal status (women only) 0.029
Postmenopausal 71 (41.8) 59 (42.8) 60 (44.1) 66 (55.7)
Premenopausal 82 (48.2) 65 (47.1) 67 (49.3) 46 (38.3)
Perimenopausal 17 (10.0) 14 (10.1) 9 (6.6) 8 (6.7)
Parity 0.065
None 21 (12.4) 13 (9.4) 15 (11.0) 11 (9.2)
1–2 117 (68.8) 93 (67.4) 84 (61.8) 66 (55.0)
>2 32 (18.8) 32 (23.2) 37 (27.2) 43 (35.8)
Menarche (years) 0.76
Before 15 157 (92.4) 124 (89.9) 126 (92.6) 108 (90.0)
After 15 13 (7.6) 14 (10.1) 10 (7.4) 12 (10.0)
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proximal colon cases, the results were similar to those
found for colorectal cancer in general, with significantly
increased cancer risk in those with the highest quartile of
PAI-1 levels; however, for distal colon and rectal cancer
cases, the risk was not related to PAI-1 levels.
Breast cancer
Table 3 shows HR and 95% CI for developing breast
cancer in relation to PAI-1 levels in the women popula-
tion and by menopausal status. After adjusting for age
and sex and stratifying by centre an increased risk of
breast cancer was observed for increasing levels of PAI-1
(HRVIvsI=1.70 (1.21 to 2.39). Additional adjustment for
BMI or waist circumference, smoking habits, total phys-
ical activity, education, menopausal status and parity and
age at menarche (HRVIvsI=1.66 (1.14 to 2.42) and
further adjustment for metabolic variables did not
modify the results (HRVIvsI=1.66 (1.14 to 2.43) and 1.60
(1.07 to 2.40) (figure 1). Excluding case participants
who were diagnosed within 1 year after blood draw
(n=35) also provided similar results (HRIVvsI=1.64, 95%
CI 1.09 to 2.47, P for trend=0.032). The risk of breast
cancer increased by 21% for each increase in 1 SD of
PAI-1 levels.
Stratification for menopausal status, showed that the
association was only present in postmenopausal women
(HRVIvsI=2.36 (1.37 to 4.06), (P for interaction (postme-
nopausal vs premenopausal): p=0.021).
Acute coronary syndromes
Table 4 shows HR and 95% CI for developing ACS in rela-
tion to PAI-1 levels in the whole population and by
gender. Individuals in the highest compared with the
lowest quartile of PAI-1 had significantly increased risks
of ACS (HR 2.57; 95% CI 1.75 to 3.77; P for trend<0.001)
after adjusting for age and sex and stratifying by centre.
Adjustment for possible confounders, including meta-
bolic factors, slightly decreased the risk that remained
statistically significant (models 2–4, figure 1). The risk of
ACS increased by 26% for each increase in 1 SD of PAI-1
levels. The effect was more evident in men.
Ischaemic stroke
Individuals in the highest compared with the lowest
quartile of PAI-1 had significantly increased risks of
ischaemic stroke (HR 2.27; 95% CI 1.28 to 4.03; P for
trend<0.0017) after adjusting for age and sex and strati-
fying by centre (table 5). Adjustment for possible con-
founders, including metabolic factors, slightly decreased
the risk that remained statistically significant (models 2–
4, figure 1). The risk of ischaemic stroke increased by
17% for each increase in 1 SD of PAI-1 levels.
Table 2 HR (95% CI) for developing colorectal cancer in relation to plasminogen activator inhibitor-1 (PAI-1) levels
Quartiles of PAI-1
P for trend
(median)
Continuous
(for every SD
increase)I II III IV
All the participants
Events/
subcohort
42/213 66/212 83/213 112/212
HR* -1- 1.31 (0.82 to 2.11) 1.65 (1.05 to 2.60) 2.28 (1.46 to 3.55) 0.0001 1.30 (1.13 to 1.49)
HR† -1- 1.25 (0.77 to 2.03) 1.59 (1.00 to 2.53) 2.17 (1.34 to 3.50) 0.0008 1.28 (1.10 to 1.50)
HR‡ -1- 1.24 (0.76 to 2.03) 1.61 (1.01 to 2.58) 2.20 (1.36 to 3.57) 0.0007 1.29 (1.10 to 1.52)
HR§ -1- 1.24 (0.76 to 2.04) 1.48 (0.92 to 2.37) 1.84 (1.11 to 3.04) 0.018 1.22 (1.02 to 1.44)
Men¶
Events/
subcohort
11/43 25/74 38/77 70/92
HR* -1- 0.94 (0.37 to 2.36) 1.45 (0.61 to 3.45) 2.86 (1.23 to 6.66) 0.0003 1.59 (1.27 to 2.00)
HR† -1- 0.96 (0.34 to 2.72) 1.38 (0.54 to 3.53) 2.84 (1.11 to 7.29) 0.0011 1.58 (1.24 to 2.01)
HR‡ -1- 1.02 (0.35 to 2.99) 1.75 (0.66 to 4.63) 3.64 (1.37 to 9.69) 0.0002 1.75 (1.37 to 2.24)
HR§ -1- 0.92 (0.30 to 2.82) 1.46 (0.53 to 4.01) 2.60 (0.93 to 7.26) 0.0064 1.53 (1.18 to 1.98)
Women¶
Events/
subcohort
31/170 41/138 45/136 42/120
HR* -1- 1.63 (0.95 to 2.79) 1.76 (1.04 to 3.00) 1.79 (1.03 to 3.11) 0.062 1.16 (0.97 to 1.38)
HR† -1- 1.56 (0.90 to 2.70) 1.73 (1.01 to 2.96) 1.77 (0.98 to 3.20) 0.083 1.15 (0.95 to 1.40)
HR‡ -1- 1.61 (0.93 to 2.79) 1.76 (1.03 to 3.01) 1.72 (0.95 to 3.11) 0.11 1.13 (0.92 to 1.37)
HR§ -1- 1.64 (0.94 to 2.86) 1.73 (1.01 to 2.98) 1.64 (0.87 to 3.08) 0.18 1.12 (0.90 to 1.38)
*Adjusted for age and sex; stratified by centre.
†Adjusted for age, sex, body mass index, smoking habits, total physical activity and education; stratified by centre.
‡As model 2, further adjusted for insulin; stratified by centre.
§As model 3, further adjusted for glucose, triglycerides and C reactive protein, stratified by centre. Thirty-two participants are excluded from
this analysis because of missing values for glucose or C reactive protein.
¶p for interaction (men vs women): p=0.040 for model 2 and p=0.034 for model 3.
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Figure 1 HRs (95% CI) for developing breast cancer (diamond), colon-rectal cancer (triangle), acute coronary syndromes
(circle) or stroke (square) in relation to quartiles of plasma concentration of PAI-1. HRs are stratified by centre and adjusted for
age, body mass index, smoking habits, total physical activity, education, insulin, C reactive protein, glucose, triglycerides,
menopausal status, parity and age at menarche (only for breast cancer), hypertension, diabetes, hyperlipidaemia (only for acute
coronary syndromes and stroke).
Table 3 HR (95% CI) for developing breast cancer in relation to PAI-1 levels
Quartiles of PAI-1
P trend
(median)
Continuous
(for every SD
increase)I II III IV
All the women
Events/subcohort 140/170 156/138 157/136 164/120
HR* -1- 1.40 (1.00 to 1.95) 1.44 (1.03 to 2.00) 1.70 (1.21 to 2.39) 0.0055 1.20 (1.06 to 1.35)
HR† -1- 1.41 (1.01 to 2.00) 1.41 (1.00 to 1.99) 1.66 (1.14 to 2.42) 0.018 1.19 (1.04 to 1.36)
HR‡ -1- 1.41 (1.01 to 2.00) 1.41 (0.99 to 1.99) 1.66 (1.14 to 2.43) 0.019 1.19 (1.04 to 1.37)
HR§ -1- 1.38 (0.98 to 1.95) 1.41 (0.99 to 2.00) 1.60 (1.07 to 2.40) 0.035 1.21 (1.05 to 1.40)
Premenopausal status¶
Events/subcohort 82/82 78/65 56/67 50/46
HR* -1- 1.22 (0.76 to 1.95) 0.79 (0.47 to 1.31) 0.92 (0.53 to 1.62) 0.52 1.03 (0.83 to 1.27)
HR† -1- 1.13 (0.68 to 1.87) 0.82 (0.48 to 1.41) 1.02 (0.55 to 1.89) 0.84 1.07 (0.85 to 1.34)
HR‡ -1- 1.13 (0.69 to 1.87) 0.81 (0.47 to 1.40) 0.98 (0.52 to 1.84) 0.74 1.06 (0.84 to 1.33)
HR§ -1- 1.18 (0.70 to 1.98) 0.82 (0.46 to 1.44) 1.14 (0.57 to 2.27) 0.94 1.17 (0.89 to 1.53)
Postmenopausal status¶
Events/subcohort 47/71 66/59 89/60 100/66
HR* -1- 1.78 (1.06 to 3.00) 2.36 (1.44 to 3.85) 2.56 (1.56 to 4.20) 0.0006 1.28 (1.09 to 1.51)
HR† -1- 1.79 (1.05 to 3.07) 2.26 (1.35 to 3.78) 2.35 (1.37 to 4.03) 0.0070 1.24 (1.03 to 1.49)
HR‡ -1- 1.79 (1.04 to 3.07) 2.26 (1.35 to 3.78) 2.36 (1.37 to 4.06) 0.0063 1.26 (1.04 to 1.53)
HR§ -1- 1.70 (0.98 to 2.94) 2.15 (1.26 to 3.67) 2.14 (1.20 to 3.82) 0.024 1.22 (1.00 to 1.49)
*Adjusted for age; stratified by centre.
†Adjusted for age, BMI, smoking habits, total physical activity, education, menopausal status, parity and age at menarche; stratified by centre.
‡As model 2, further adjusted for insulin, stratified by centre.
§As model 3, further adjusted for glucose, triglycerides and C reactive protein, stratified by centre; 20 participants are excluded from this
analysis because of missing values for glucose or C reactive protein.
¶p for interaction (postmenopausal vs premenopausal): p=0.021 for model 2 and p=0.021 for model 3.
BMI, body mass index, PAI-1, plasminogen activator inhibitor-1.
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DISCUSSION
Evidence is presently accumulating, that ischaemic car-
diovascular disease and several forms of cancers share
some common mechanisms, as if they were two trees
emerging from the same district of earth, with inter-
mingled roots.1 2
In this case-cohort study, we have now found that high
plasma levels of PAI-1 could be a common marker of some
mechanisms shared by cancer and cardiovascular disease;
indeed, PAI-1 levels were positively and independently
associated with an increased risk of colorectal cancer,
breast cancer, ACS and ischaemic stroke (figure 1).
Table 4 HR (95% CI) for developing ACS in relation to PAI-1 levels
Quartiles of PAI-1
P for trend
(median)
Continuous
(for every SD
increase)I II III IV
All the participants
Events/
subcohort*
72/217 140/208 194/209 282/206
HR† -1- 1.42 (0.95 to 2.14) 1.88 (1.27 to 2.78) 2.57 (1.75 to 3.77) <0.001 1.41 (1.26 to 1.58)
HR‡ -1- 1.04 (0.65 to 1.68) 1.54 (0.98 to 2.42) 1.81 (1.14 to 2.86) 0.0037 1.25 (1.09 to 1.43)
HR§ -1- 1.04 (0.65 to 1.68) 1.55 (0.98 to 2.44) 1.82 (1.15 to 2.89) 0.0035 1.25 (1.09 to 1.43)
HR¶ -1- 1.10 (0.70 to 1.72) 1.27 (0.83 to 1.96) 1.70 (1.09 to 2.65) 0.011 1.26 (1.10 to 1.45)
Men**
Events/
sub-cohort
42/43 88/74 145/76 196/91
HR† -1- 1.01 (0.55 to 1.83) 1.57 (0.89 to 2.77) 2.03 (1.17 to 3.53) 0.0013 1.44 (1.21 to 1.71)
HR‡ -1- 0.70 (0.34 to 1.47) 1.34 (0.68 to 2.63) 1.49 (0.76 to 2.94) 0.031 1.28 (1.04 to 1.58)
HR§ -1- 0.71 (0.34 to 1.48) 1.39 (0.70 to 2.75) 1.54 (0.78 to 3.07) 0.026 1.29 (1.05 to 1.60)
HR¶ -1- 0.80 (0.39 to 1.62) 1.04 (0.54 to 1.99) 1.52 (0.78 to 2.94) 0.027 1.38 (1.12 to 1.71)
Women**
Events/
sub-cohort
30/174 52/134 49/133 86/115
HR† -1- 2.29 (1.35 to 3.88) 2.11 (1.24 to 3.60) 3.54 (2.11 to 5.98) <0.001 1.42 (1.23 to 1.61)
HR‡ -1- 1.89 (1.06 to 3.36) 1.68 (0.90 to 3.13) 2.16 (1.16 to 4.00) 0.059 1.18 (1.01 to 1.38)
HR§ -1- 1.93 (1.08 to 3.44) 1.70 (0.91 to 3.19) 2.13 (1.15 to 3.94) 0.070 1.17 (1.00 to 1.37)
HR¶ -1- 1.86 (1.05 to 3.29) 1.76 (0.99 to 3.15) 2.02 (1.08 to 3.80) 0.098 1.17 (0.97 to 1.40)
*Among participants of the subcohort, n=10 non-cases were eliminated from the analysis because of relevant missing data.
†Adjusted for age and sex; stratified by centre.
‡Adjusted for age, sex, BMI, smoking habits, total physical activity, education, hypertension, diabetes and hyperlipidaemia; stratified by
centre.
§As model 2, further adjusted for insulin; stratified by centre.
¶As model 3, further adjusted for glucose, triglycerides and C reactive protein, stratified by centre. Thirty-two participants are excluded from
this analysis because of missing values for glucose or C reactive protein.
**p for interaction (men vs women): p=0.69 for model 2 and p=0.67 for model 3.
ACS, acute coronary syndrome; BMI, body mass index; PAI-1, plasminogen activator inhibitor-1.
Table 5 HR (95% CI) for developing ischaemic stroke in relation to PAI-1 levels
Quartiles of PAI-1
P for trend
(median)
Continuous
(for every SD
increase)I II III IV
Events/
subcohort*
26/217 27/208 45/209 61/206
HR† -1- 1.19 (0.63 to 2.25) 1.71 (0.96 to 3.03) 2.27 (1.28 to 4.03) 0.0017 1.24 (1.05 to 1.47)
HR‡ -1- 1.06 (0.54 to 2.10) 1.49 (0.81 to 2.77) 1.86 (1.00 to 3.47) 0.023 1.14 (0.95 to 1.36)
HR§ -1- 1.09 (0.55 to 2.14) 1.59 (0.85 to 2.95) 2.18 (1.17 to 4.07) 0.0051 1.22 (1.01 to 1.47)
HR¶ -1- 1.14 (0.58 to 2.24) 1.72 (0.95 to 3.14) 2.02 (1.06 to 3.84) 0.021 1.17 (0.94 to 1.44)
*Among participants of the subcohort, n=10 non-cases were eliminated from the analysis because of relevant missing data.
†Adjusted for age and sex; stratified by centre.
‡Adjusted for age, sex, BMI, smoking habit, total physical activity, education, hypertension, diabetes and hyperlipidaemia; stratified by centre.
§As model 2, further adjusted for insulin; stratified by centre.
¶As model 3, further adjusted for glucose, triglycerides and C reactive protein, stratified by centre. Thirty-two participants are excluded from
this analysis because of missing values for glucose or C reactive protein.
BMI, body mass index; PAI-1, plasminogen activator inhibitor-1.
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The risk increase was greater for men in colorectal
cancer as well as in ACS, while in women, it was not sig-
nificant for colorectal cancer. Regarding individual sub-
sites, the increase in risk was significant for whole colon,
and proximal colon cases, but not for distal colon and
rectum cases.
Our data also show, in the cohort subset of women, a
similar association between high PAI-1 levels and
increased risk of breast cancer; the association was
evident in postmenopausal women, not in premenopau-
sal participants.
The association between high PAI-1 levels and each of
the diseases studied was independent from possible con-
founders, obesity and insulin levels included. Adipocytes
might secrete PAI-1 in response to insulin and other
metabolic mediators32 and insulin is able to release PAI-1
from several cell types33; as a consequence obese partici-
pants or those with high levels of insulin showed high
levels of PAI-1.24 Since obesity and high levels of insulin
have been associated with the risk of cancer or ischaemic
vascular disease,34 35 the observed results for PAI-1 might
only mask a relation of cancer or ischaemic vascular
disease with obesity or insulin. However, adjustment for
obesity (or waist circumference), insulin or other meta-
bolic parameters did not modify the associations found.
In patients with cancer, association of high levels of
PAI-1 with poor prognosis has been documented16-21;
however, to our knowledge, this is the first epidemio-
logical evidence of a predictive value of PAI-1 on cancer
risk in apparently healthy participants. To exclude the
possibility that the increase in PAI-1 could reflect the
presence of an occult disease, we excluded from an add-
itional analysis those participants who were diagnosed
with a cancer within 1 year from their inclusion into the
study and analysed the association according to
follow-up length (data not shown). In both cases and for
both cancers the results did not change compared to
our principal analyses.
The interpretation of our findings is challenging
because in humans the activities of PAI-1 that might be
relevant for tumourigenesis are not entirely clear. In
haemostasis, the primary role of PAI-1 is to stabilise the
haemostatic plug formation via inhibition of t-PA with sub-
sequent inhibition of fibrinolysis.6 Elevated levels of PAI-1
have long been associated with thrombosis.4–9 However,
there is emerging evidence that PAI-1 may also participate
in the pathophysiology of cancer. The latter role of PAI-1 is
not solely explained by the protease inhibitor activity of
PAI-1, but should rely on the ability of PAI-1 to alter cell
signalling, indicating that PAI-1 can directly promote pro-
proliferative and antiapoptotic signalling in a variety of cell
types.36 PAI-1 is supposed to foster cancer onset and pro-
gression through multiple activities, although its role is
counterintuitive, as it inhibits u-PA, which promotes
matrix degradation and cancer invasion (reviewed in Ref.
37). In knock-out mice, the absence of PAI-1 prevents
cancer invasion and vascularisation,13 again supporting
the role of blood coagulation in angiogenesis regulation.
Experimental studies in knock-out mice have demon-
strated that host PAI-1 is an essential factor of the host
microenvironment, promoting early steps of skin carcin-
oma progression.38
Strengths and limitations of this study
Major strengths of our study are its prospective design,
relative large sample size, multiple endpoints and use of
detailed information on lifestyle, anthropometric and
biological variables, allowing to control for their possible
confounding effect.
In contrast, a limitation of the present study is that, as
it occurs in the greatest majority of large prospective
cohort studies, for each participant the PAI-1 level could
only be assessed in a single plasma sample; thus, indica-
tions of long-term variation in its levels since baseline
are lacking. However, any of such changes are likely to
weaken the association between PAI-1 and cancer. There
is also the problem of a possible short-term intraindivi-
dual variation in the analyte level, since data suggest a
large variation,39 although the differences found
between cases and controls are greater.
Another limitation is that samples were stored after
collection at −196°C, and assayed up to 17 years later,
thus the possibility of a variable PAI-1 concentration
decay during long-term storage cannot be excluded.
However, recent data indicate that long-term storage
affects PAI-1 antigen levels to a negligible extent.40
Finally, it should be considered that association is not
necessarily equal to causation and PAI-1 could be a
by-product (or a marker) of an as yet undefined
‘common soil’ mechanism.
To conclude, the findings of this prospective study
indicate that elevated plasma levels of PAI-1 are potential
risk factors for colorectal and breast cancer and a
common pathway between cancer and ischaemic cardio-
vascular disease.
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